Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New research reveals a key reason why: two closely related proteins, BRD2 and BRD4, don’t actually do the same job. Instead, BRD2 acts like a “stage manager,” preparing genes for activation, while BRD4 triggers the final step that turns them on. By blocking both at once, current drugs may be disrupting the process in unpredictable ways.
Source: https://www.sciencedaily.com/releases/2 ... 101055.htm
-
Translation